Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIXIR study of Xylocore for peritoneal dialysis
2024-513562-19-00Phase 3Authorised
- Sponsor
- Iperboreal Pharma
- Start
- Dec 2022
- Modality
- Gene Therapies
- Countries
- 6
01
Overview
Phase 3 trial of encoberminogene rezmadenovec in end-stage kidney disease (ESKD) (2 arms), sponsored by Iperboreal Pharma. Primary endpoint: Weekly Kt/V urea. Planned start Dec 2022; status: authorised.
02
Drugs
encoberminogene rezmadenovec
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2024-513562-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513562-19-00.